We agree with Mistry et al. (2011) that quantification of the future burden of cancer incidence is vital in health-care planning and that where risk factors are not well understood (as is the case for the majority of haematological cancers) projections from observed trends provide the best available evidence to achieve this. However, we are concerned that the projections they have recently published for haematological cancers, and which are widely disseminated via the Cancer Research UK CancerStats website (Cancer Research UK, 2012), are not credible and are likely to be based on incomplete data.
Projections based on the CIS data set showed very different results from those published, with increasing age-standardised rates for all three forms of haematological cancers in both sexes (see Table 1 ). We did not observe any downward trends in agespecific incidence rates for myeloma or leukaemia in the English CIS data and we believe that the published projections may have been based on incomplete registration data for the latter period of their time series. Although we were not fully replicating their analyses and used a shorter time series and a sub-population of the UK, we do not believe this could explain the differences observed.
Haematological cancers present particular problems for the accurate estimation of incidence through routine cancer registration systems. A variety of factors may make past trends a relatively poor predictor of future incidence, so our projections should be viewed with caution. However, we believe they represent a more realistic estimate of the likely trends in incidence over the next two decades. It will be important to resolve the reasons for differences between routine cancer registration data sets under-pinning these projections for haematological cancers and also to establish if there is any impact on other disease-specific projections.
